A Real-World Look at a Migraine Preventive

Randomized trials tell you whether a drug can work under tightly controlled conditions. They do not always tell you how well it works once it reaches real clinics, real schedules, and people who would never have qualified for the original study. That gap matters for migraine, where preventive treatment is a long game and adherence often decides the outcome.

A 2026 systematic review and meta-analysis in Expert Review of Neurotherapeutics pooled real-world studies of fremanezumab, one of the monoclonal antibodies that block calcitonin gene-related peptide (CGRP) signaling. The headline finding: in everyday practice, fremanezumab cut monthly migraine days by close to six, and about half of people reached the meaningful threshold of a 50% or greater reduction within three months. Those effect sizes are larger than the placebo-adjusted numbers from the pivotal trials, which is what you would expect when you remove the placebo arm and look at how people actually do.

How CGRP and Fremanezumab Actually Work

CGRP is a small signaling peptide released around the trigeminal nerve, the sensory system that carries pain from the head and face. During a migraine attack, CGRP levels rise, blood vessels in the meninges dilate, and the trigeminal pain pathway becomes sensitized. That sensitization is a big part of why light, sound, movement, and even gentle touch start to hurt during an attack. Block CGRP and you blunt this cascade at one of its key relay points.

This is a different strategy from the older preventives. Drugs like propranolol, topiramate, and amitriptyline were all borrowed from other fields (blood pressure, epilepsy, depression) and happen to reduce migraine frequency through broader, less specific mechanisms. They work for some people, but tolerability is often the problem: fatigue, brain fog, weight change, and mood effects drive many people to quit. Fremanezumab was built for migraine from the start, which tends to show up as cleaner tolerability rather than dramatically higher peak efficacy.

What the Study Found

The authors searched PubMed, Scopus, and Web of Science through November 2025 and pooled real-world studies that measured monthly migraine days (MMDs), monthly headache days (MHDs), and the Headache Impact Test (HIT-6), a validated disability score. They used random-effects models, which is the appropriate choice when pooling studies that differ in setting and population.

Monthly headache days fell by 7.30 days (95% CI: -9.72 to -4.87). The "50% responder" rate is the number clinicians and patients tend to care about most, because halving attack frequency is often the difference between migraine running your calendar and you running it. Importantly, response was not a one-month flash. It built over time, which fits what headache specialists see in clinic: the people who stay on a CGRP antibody for several months often do better than their first-month numbers predict.

Where Fremanezumab Fits in Treatment

Preventive treatment is worth discussing once migraine attacks are frequent (a common trigger is four or more migraine days a month, or fewer if attacks are severe and disabling), when acute medications are not enough or are being used too often, or when attacks are seriously disrupting work and life. The goal of prevention is not zero attacks. It is fewer and milder attacks, less reliance on acute drugs, and less disability.

For years, CGRP antibodies were positioned as a later-line option you reached only after a couple of cheaper oral preventives had failed. That has shifted. In 2024 the American Headache Society updated its position statement to say that CGRP-targeting therapies can be used first-line for migraine prevention, without requiring prior failure of older drug classes. Their reasoning was that the evidence base for efficacy, tolerability, and safety now exceeds that of any other preventive approach. Insurance coverage rules in many places still lag behind this guidance and may require step therapy, so the practical path can differ from the clinical ideal.

"The most useful way to read this analysis is not as a sales pitch for one drug, but as confirmation that the real-world payoff of CGRP prevention holds up outside the trial bubble. The question worth bringing to your clinician is whether your attack frequency and disability justify prevention at all, and if so, whether a migraine-specific option fits you better than starting with an older pill." - Cerebral Torque

Fremanezumab in Context: Dosing and Evidence

How fremanezumab is dosed, alongside the other main preventive approaches, with an honest read on the strength of the evidence behind each. Scroll the table sideways on smaller screens.

Evidence key: Strong = supported by randomized controlled trials. Moderate / Supported = real-world and trial data support use, with caveats. Limited = weaker or mixed evidence; reasonable but not a primary strategy.

Fremanezumab is one option inside a now-crowded CGRP class. The meta-analysis does not show it is better than its siblings; head-to-head trials are scarce. What it shows is that this specific antibody delivers the kind of real-world benefit the class is known for. If one CGRP drug does not help or is not covered, switching within the class is a standard and reasonable move.

Who It Helps Most

One detail from the broader fremanezumab evidence is worth pulling out for anyone stuck in the rebound-headache trap. In the chronic-migraine trial program, fremanezumab reduced headache days whether or not people were overusing acute medication, and more treated people reverted to no medication overuse than those on placebo. That matters because medication-overuse headache is one of the hardest patterns to break, and a preventive that helps loosen it is genuinely useful.

People with migraine who have aura can use CGRP antibodies; aura itself is not a barrier. Pregnancy is a different story, covered below.

Safety, Side Effects, and Cautions

One of the consistent selling points of CGRP antibodies is how little tends to go wrong. In this meta-analysis, the pooled adverse-event rate was about 5% over six months and 7% over twelve months, with constipation the most commonly reported issue. That is a low number, and it lines up with years of trial and real-world data.

The honest caveats: CGRP is involved in blood-vessel function, so caution is reasonable in people with significant cardiovascular or cerebrovascular disease even though trials have not flagged a clear signal of harm. Constipation is occasionally severe and worth reporting if it does not settle. And because these drugs are relatively new, long-term pregnancy data are thin, so they are generally avoided or carefully discussed if you are pregnant, trying to conceive, or breastfeeding. None of these are reasons to avoid the drug for most people. They are reasons to have a real conversation with your prescriber.

Practical Guidance

If you and your clinician decide to try fremanezumab, a few things make the experience smoother and the decision clearer.

• Keep tracking attacks. A simple headache diary, on paper or in an app, is the only way to know if you are actually hitting that 50% reduction. Memory tends to overweight the bad weeks.
• Give it a fair trial. Benefit can build over months, so a common approach is to reassess at around three months rather than judging it after a single dose.
• Do not stop your acute plan cold. Prevention lowers frequency; you still need a reliable acute treatment for the attacks that get through.
• Keep the foundation in place. Regular sleep, steady meals and hydration, exercise, and stress tools are not a substitute for medication, but they meaningfully raise the floor.
• Plan around coverage. Insurance may require trying an older preventive first. Knowing this ahead of time saves frustration, and manufacturer support programs sometimes help with cost.

The Bottom Line

This meta-analysis will not change the fundamentals of how fremanezumab is prescribed, and it does not need to. What it does is reassure people on the fence: the real-world benefit of CGRP prevention is real, durable, and well tolerated, with roughly half of users halving their attack frequency and disability scores improving in step. Combined with the 2024 shift toward treating CGRP drugs as a legitimate first-line choice, the practical takeaway is that frequent, disabling migraine deserves a serious preventive conversation sooner rather than later.